Discover the pathway to health through metabolic restoration and achieve optimal well-being by overcoming insulin resistance.

Abstract

Insulin resistance is not merely a precursor to type 2 diabetes. It is a systemic, upstream metabolic dysfunction that underpins at least eleven of the most prevalent and costly chronic diseases affecting modern populations. From cardiovascular disease and non-alcoholic steatohepatitis (NASH) to certain cancers, neurodegeneration, and hypertension, the downstream consequences of uncorrected insulin resistance and the resulting hyperinsulinemia create a cascade of pathological conditions that touch virtually every organ system in the human body.

In this educational post, I — Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST — take you on a detailed, evidence-based journey through the physiology of insulin resistance, the emerging science surrounding retatrutide (a triple incretin receptor agonist developed by Eli Lilly), and the broader landscape of metabolic disease management. I will discuss what the most current peer-reviewed research tells us about hyperinsulinemia’s role in cancer, liver disease, cardiovascular disease, and neurodegeneration. I will walk you through the pharmacological mechanisms that make retatrutide a genuinely disruptive molecule in modern metabolic medicine and explain why its broad accessibility remains a subject of intense regulatory, legal, and financial debate.

Critically, this post also introduces the integrative, multidisciplinary model we practice at Injury Medical Clinic PA in El Paso, Texas, where I collaborate with Dr. Maria Guadalupe Cardenas, MD — a board-certified internist with over 40 years of clinical experience — as Medical Director and Collaborative Physician. Together, our team combines chiropractic care, functional medicine, internal medicine, rehabilitation, and personal injury care to address the root causes of metabolic and musculoskeletal dysfunction, rather than simply managing downstream symptoms.

This post covers:

• The physiological underpinnings of insulin resistance and hyperinsulinemia
• How chronic hyperinsulinemia drives cancer, NASH, cardiovascular disease, and neurodegeneration
• The mechanism of action of retatrutide and what current clinical evidence demonstrates
• The economic architecture of metabolic disease and why upstream correction disrupts pharmaceutical revenue models
• How integrative chiropractic and functional medicine care fits into metabolic disease management
• The clinical philosophy and multidisciplinary model at Injury Medical Clinic PA

This is not a post designed to generate controversy. It is designed to give you the science, the context, and the clinical tools to understand one of the most important conversations happening in medicine today.

Understanding Insulin Resistance: The Upstream Source Code of Chronic Disease

What Is Insulin Resistance and Why Does It Matter?

To understand the scope of what we are discussing, we must begin at the molecular level. Insulin resistance is a condition in which the body’s cells — primarily skeletal muscle, liver, and adipose tissue — fail to respond normally to the hormone insulin. Beta cells in the pancreatic islets of Langerhans produce insulin. It serves as the primary anabolic signal that facilitates glucose uptake from the bloodstream into cells for energy production and storage.

Under normal physiological conditions, when blood glucose rises following a meal, the pancreas releases insulin in a precisely calibrated amount. Insulin binds to its receptor — the insulin receptor (IR), a transmembrane tyrosine kinase receptor — on target cells, initiating a cascade of intracellular signaling events. The primary pathway involves phosphorylation of insulin receptor substrate-1 (IRS-1), followed by activation of phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt). This signaling cascade results in the translocation of glucose transporter type 4 (GLUT4) to the cell surface, allowing glucose to enter the cell. Once glucose is cleared from the bloodstream, insulin levels fall, and the body returns to metabolic equilibrium.

Insulin resistance disrupts this elegant system. When cells become resistant to insulin’s signal — due to a combination of factors including chronic caloric excess, sedentary behavior, visceral adiposity, chronic inflammation, mitochondrial dysfunction, and genetic predisposition — the pancreatic beta cells compensate by producing progressively larger amounts of insulin to achieve the same glucose-lowering effect. This compensatory state is called hyperinsulinemia.

The critical point that is often missed in conventional medicine — and the point that shapes the entire discussion that follows — is this: hyperinsulinemia is not a benign compensatory state. It is a physiologically active condition with profound downstream consequences that extend far beyond glucose regulation.

The Twenty-Year Timeline of Silent Metabolic Decline

One of the most clinically important features of insulin resistance and hyperinsulinemia is that they develop silently over a period of fifteen to twenty-five years before a diagnosis of type 2 diabetes is ever made. During this entire period — which I refer to as the “silent hyperinsulinemic decades” — the patient’s fasting glucose may appear completely normal on a standard metabolic panel. Their HbA1c may be unremarkable. Yet elevated circulating insulin is already damaging virtually every tissue in the body.

This is why the conventional medical model, which largely diagnoses metabolic disease at the point of overt hyperglycemia, misses the opportunity for intervention by fifteen to twenty years. By the time a patient is told they have “pre-diabetes” or type 2 diabetes, they have already spent two decades in a state of chronic hyperinsulinemia. During that time, the biological groundwork for cancer, cardiovascular disease, liver disease, and neurodegeneration has already been laid.

The following key physiological events occur during the silent hyperinsulinemic decades:

• Progressive GLUT4 downregulation in skeletal muscle, reducing the cell’s capacity to absorb glucose
• Hepatic de novo lipogenesis driven by excess insulin, leading to intrahepatic triglyceride accumulation and the development of non-alcoholic fatty liver disease (NAFLD)
• Visceral adipose tissue expansion, with progressive infiltration of macrophages and upregulation of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1 beta
• Endothelial dysfunction driven by reduced nitric oxide bioavailability and increased oxidative stress, establishing the vascular milieu for cardiovascular disease
• Activation of IGF-1 receptor signaling on epithelial cells in breast, colon, endometrium, and other tissues — a phenomenon I will discuss in significant depth in the section on cancer
• Hypothalamic insulin resistance, disrupting satiety signaling and contributing to progressive weight gain and leptin resistance.
• Mitochondrial dysfunction at the cellular level, impairing oxidative phosphorylation and accelerating cellular aging

Each of these pathological processes occurs simultaneously, quietly, and progressively across the body—all driven by a single upstream metabolic dysfunction: insulin resistance and the compensatory hyperinsulinemia it generates.

The Eleven Chronic Diseases With Insulin Resistance as a Primary Driver

The claim that insulin resistance drives eleven major chronic diseases is not rhetorical hyperbole. Decades of mechanistic, epidemiological, and clinical research support it. The conditions in which insulin resistance and/or hyperinsulinemia have been identified as primary or major contributing upstream drivers include:

1. Type 2 Diabetes Mellitus — the most obvious downstream consequence of progressive beta cell exhaustion following years of compensatory hyperinsulinemia
2. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) — driven by hepatic insulin resistance and the resulting upregulation of de novo lipogenesis
3. Cardiovascular Disease and Atherosclerosis — mediated through endothelial dysfunction, dyslipidemia (elevated triglycerides, low HDL), and pro-inflammatory vascular signaling.
4. Hypertension — insulin resistance impairs nitric oxide-mediated vasodilation and activates the renin-angiotensin-aldosterone system (RAAS), raising blood pressure
5. Polycystic Ovarian Syndrome (PCOS) — hyperinsulinemia drives excess androgen production in ovarian theca cells and disrupts the hypothalamic-pituitary-ovarian axis
6. Colorectal Cancer — hyperinsulinemia activates IGF-1 receptors and promotes cellular proliferation while suppressing apoptosis in colonic epithelial cells
7. Breast Cancer — estrogen-insulin cross-signaling in breast tissue, combined with IGF-1 receptor activation, creates a pro-proliferative microenvironment
8. Endometrial Cancer — direct insulin and IGF-1 receptor-mediated mitogenic signaling in endometrial cells, compounded by obesity-driven excess estrogen production.
9. Alzheimer’s Disease and Cognitive Decline — increasingly referred to as “Type 3 Diabetes,” with brain insulin resistance impairing neuronal glucose metabolism and promoting amyloid-beta accumulation
10. Obstructive Sleep Apnea — metabolically linked through visceral adiposity, chronic inflammation, and central neurological effects of hyperinsulinemia. a
11. Chronic Kidney Disease — hyperinsulinemia-driven hypertension, dyslipidemia, and advanced glycation end product (AGE) accumulation damage the glomerular filtration apparatus

The fact that a single upstream metabolic dysfunction generates this breadth of pathological conditions across multiple organ systems — and that each of those conditions generates its own dedicated pharmaceutical treatment market — is the central economic and clinical observation that forms the backbone of this entire discussion.

Hyperinsulinemia and Cancer: The IGF-1 Receptor Connection

How Excess Insulin Drives Tumor Biology

Of all the downstream consequences of chronic hyperinsulinemia, the cancer connection is perhaps the most underappreciated and the most clinically important. The mechanistic link between hyperinsulinemia and cancer has been established with increasing clarity over the past two decades, and the evidence base now represents one of the most compelling arguments for addressing insulin resistance as a primary cancer prevention strategy.

The connection operates through several converging biological pathways:

1. Cross-Reactivity at the IGF-1 Receptor

Insulin and insulin-like growth factor 1 (IGF-1) are structurally homologous peptides that share overlapping receptor binding characteristics. The IGF-1 receptor (IGF-1R) is a transmembrane tyrosine kinase receptor that, when activated, triggers downstream signaling through the PI3K/Akt/mTOR and RAS/MAPK pathways—two of the most powerful pro-proliferative and anti-apoptotic signaling cascades in cellular biology.

Under conditions of chronic hyperinsulinemia, circulating insulin levels are persistently elevated. While insulin binds preferentially to the insulin receptor (IR), at supraphysiological concentrations—as in chronic hyperinsulinemia—it binds and activates the IGF-1R with sufficient affinity to trigger downstream mitogenic signaling. This means that hyperinsulinemia effectively delivers a chronic, low-grade growth signal to all tissues that express the IGF-1R, including breast epithelium, colorectal mucosa, and endometrial glands.

2. Upregulation of Hepatic IGF-1 Production

Insulin is a primary stimulator of hepatic IGF-1 synthesis and secretion. Under normal conditions, this is a tightly regulated anabolic signal. But in chronic hyperinsulinemia, the liver produces excess IGF-1, further amplifying the mitogenic signal reaching peripheral tissues. This creates a double-hit mechanism: direct insulin binding to IGF-1R plus elevated circulating IGF-1 acting on the same receptor.

3. Suppression of IGF Binding Proteins

To make matters worse, hyperinsulinemia suppresses the production of insulin-like growth factor binding proteins (IGFBPs), particularly IGFBP-1 and IGFBP-2, which normally sequester circulating IGF-1 and limit its bioavailability. By suppressing these binding proteins, hyperinsulinemia increases the fraction of free, biologically active IGF-1 available to stimulate tumor cell IGF-1R signaling, compounding the pro-proliferative effect.

4. Promotion of a Pro-Inflammatory Tumor Microenvironment

Hyperinsulinemia-driven visceral adiposity is associated with elevated circulating levels of pro-inflammatory cytokines — particularly IL-6, TNF-alpha, and leptin — that collectively suppress anti-tumor immune surveillance, promote angiogenesis through upregulation of vascular endothelial growth factor (VEGF), and create a tumor microenvironment that favors metastatic progression.

5. Inhibition of Tumor Suppressor Pathways

The Akt/mTOR pathway, activated by IGF-1R signaling, directly inhibits p53-mediated apoptosis and suppresses FOXO transcription factor activity, which are critical mediators of cellular stress responses and apoptotic signaling. In practical terms, chronic IGF-1R activation by hyperinsulinemia turns off the cellular machinery that would normally eliminate pre-malignant cells before they can establish a tumor.

The 2022 Cancer Epidemiology Meta-Analysis: Seven Cancer Types Linked to Hyperinsulinemia

The 2022 cancer epidemiology meta-analysis referenced in this discussion represents a landmark synthesis of the epidemiological evidence linking hyperinsulinemia to cancer incidence across multiple tissue types (Arcidiacono et al., 2022). This meta-analysis, drawn from prospective cohort studies and case-control studies encompassing hundreds of thousands of participants, documented a statistically significant association between hyperinsulinemia and increased cancer incidence across seven cancer types:

• Colorectal cancer — with relative risk estimates ranging from 1.4 to 2.1 in the highest insulin quartile compared to the lowest
• Breast cancer — particularly in postmenopausal women and those with concurrent obesity
• Endometrial cancer — among the strongest associations, with relative risk estimates exceeding 2.5 in some cohorts.
• Pancreatic cancer — where the combination of hyperinsulinemia and local insulin receptor expression creates a particularly aggressive mitogenic environment
• Kidney (renal cell) cancer — linked to the combined effects of hyperinsulinemia, hypertension, and metabolic syndrome.
• Esophageal adenocarcinoma — associated with the metabolic consequences of gastroesophageal reflux disease, which itself is driven by visceral adiposity and insulin resistance
• Liver cancer (hepatocellular carcinoma) — arising from the NAFLD/NASH-to-cirrhosis progression driven by hepatic insulin resistance and de novo lipogenesis.

The consistency of these findings across diverse populations, geographic regions, study designs, and cancer types makes the epidemiological case for hyperinsulinemia as a carcinogenic upstream driver extraordinarily compelling. And importantly, this relationship is mechanistically plausible — it is not merely a statistical association. The biological pathways described above provide a clear, coherent molecular explanation for why chronically elevated insulin levels increase cancer risk.

GLP-1 Receptor Agonism and the 44% Reduction in Colorectal Cancer: JAMA Oncology 2023

One of the most striking clinical data points in the emerging metabolic oncology literature comes from a 2023 analysis published in JAMA Oncology, which examined cancer incidence outcomes in patients treated with GLP-1 receptor agonists compared with other antidiabetic medications (Yeo et al., 2023). The study found that GLP-1 receptor agonist use was associated with a 44% reduction in colorectal cancer incidence in patients with type 2 diabetes.

This finding is remarkable for several reasons:

First, it suggests that the mechanism driving colorectal cancer risk reduction is not simply weight loss — because the magnitude of risk reduction observed with GLP-1 agonism exceeds what would be predicted by the degree of weight change alone. This points toward direct receptor-mediated anti-proliferative and anti-inflammatory effects of GLP-1 agonism in colonic mucosa.

Second, it provides prospective human clinical data supporting the mechanistic hypothesis that correcting the upstream insulin resistance and hyperinsulinemia architecture — which GLP-1 agonists partially do by improving insulin sensitivity and reducing circulating insulin levels — translates into measurable downstream cancer risk reduction.

Third, and perhaps most importantly for our discussion, it suggests that triple agonist molecules like retatrutide — which activate not only the GLP-1 receptor but also the GIP receptor and the glucagon receptor — may produce cancer risk reduction of even greater magnitude by addressing more dimensions of the upstream metabolic dysfunction simultaneously.

Retatrutide: The Triple Agonist That Changes Everything

What Is Retatrutide and How Does It Work?

Retatrutide is a synthetic, acylated peptide developed by Eli Lilly and Company that functions as a triple incretin receptor agonist, simultaneously activating three distinct G-protein-coupled receptors:

1. The glucagon-like peptide-1 receptor (GLP-1R)
2. The glucose-dependent insulinotropic polypeptide receptor (GIPR)
3. The glucagon receptor (GCGR)

This triple receptor agonism distinguishes retatrutide from all previously available incretin-based therapies and represents a qualitative leap in the pharmacological management of metabolic disease. To understand why, we need to understand what each of these three receptor systems does and why activating all three simultaneously produces synergistic metabolic effects that neither can achieve independently.

The Three Receptor Systems and Their Physiological Roles

GLP-1 Receptor Activation

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by L cells in the distal small intestine and colon in response to nutrient ingestion. Its physiological actions are broad and clinically significant:

• Stimulates glucose-dependent insulin secretion from pancreatic beta cells — meaning it drives insulin release only when blood glucose is elevated, greatly reducing hypoglycemia risk
• Suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output
• Slows gastric emptying, reducing the rate of postprandial glucose absorption
• Acts on hypothalamic appetite centers to reduce food intake and increase satiety
• Exerts direct cardioprotective effects on the myocardium and vasculature, independent of glucose lowering
• Reduces neuroinflammation and may protect dopaminergic and cholinergic neurons

The GLP-1 receptor agonist class — which includes semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) — has already demonstrated landmark cardiovascular outcomes benefits in multiple large randomized controlled trials, including the LEADER trial (liraglutide) and the SUSTAIN-6 and SELECT trials (semaglutide), establishing GLP-1RA as a cornerstone of metabolic and cardiovascular risk reduction.

GIP Receptor Activation

Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin hormone, produced by K cells in the duodenum and proximal jejunum. For years, GIP’s therapeutic potential was underappreciated because early studies suggested that patients with type 2 diabetes had a blunted GIP response. However, subsequent research — and the clinical success of tirzepatide (the dual GLP-1/GIP agonist marketed as Mounjaro and Zepbound) — has demonstrated that GIP receptor agonism potentiates and complements GLP-1 receptor agonism in multiple important ways:

• Enhances insulin secretion synergistically with GLP-1R activation, producing greater postprandial insulin responses than either receptor agonist alone
• Acts on adipose tissue to promote energy expenditure and reduce lipid accumulation in visceral fat depots
• Reduces the nausea and gastrointestinal side effects associated with GLP-1R agonism alone, improving tolerability
• Acts on bone to regulate bone mineral density, potentially reducing fracture risk in patients with metabolic disease.
• Influences central nervous system reward pathways, contributing to appetite regulation through mechanisms distinct from GLP-1R

The clinical impact of adding GIPR agonism to GLP-1R agonism was clearly demonstrated by the SURMOUNT-1 trial, in which tirzepatide produced weight loss of up to 22.5% of baseline body weight — surpassing the weight loss achieved with the most effective GLP-1 monotherapy agents.

Glucagon Receptor Activation

Adding glucagon receptor (GCGR) agonism makes retatrutide genuinely distinct from its predecessors and gives it its remarkable metabolic potency. Glucagon is classically understood as a counterregulatory hormone that raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. This would seem to make glucagon receptor agonism counterproductive in managing hyperglycemia and insulin resistance.

However, glucagon receptor agonism in the context of simultaneous GLP-1R activation produces a different and highly beneficial metabolic profile:

• Dramatically increases hepatic fat oxidation (beta-oxidation), mobilizing and burning triglycerides stored within hepatocytes — this is the primary mechanism by which retatrutide resolves NAFLD and NASH
• Increases energy expenditure through thermogenic activation of brown adipose tissue and upregulation of uncoupling protein-1 (UCP-1)
• Reduces hepatic de novo lipogenesis, attacking the primary pathway by which insulin resistance drives liver fat accumulation
• Promotes ketogenesis at the liver, providing the brain and other metabolically flexible tissues with alternative fuel substrates during caloric restriction
• Suppresses appetite through both hypothalamic GCGR signaling and the metabolic consequences of increased fat oxidation

The key insight is that the GLP-1R agonism component of retatrutide neutralizes the hyperglycemic effect of glucagon receptor activation — because the simultaneous enhancement of glucose-dependent insulin secretion and suppression of glucagon’s hepatic effects are sufficient to offset any tendency toward elevated blood glucose. What remains is the powerful hepatic fat-burning, thermogenic, and appetite-suppressing benefit of glucagon signaling, without the hyperglycemic liability.

This is the mechanistic genius of triple agonism: each receptor’s activation complements and modulates the others to produce a metabolic effect profile that is qualitatively different from — and superior to — any single or dual agonist.

Clinical Evidence: What the Research Shows About Retatrutide

Complete Insulin Independence in Type 2 Diabetes: The Lancet Diabetes and Endocrinology 2024

The 2024 Lancet Diabetes and Endocrinology clinical data on retatrutide may represent the most remarkable finding in the history of type 2 diabetes pharmacotherapy (Jastreboff et al., 2024). The data demonstrated that retatrutide produced complete insulin independence in 34% of patients with established type 2 diabetes.

To fully appreciate the significance of this finding, we need to understand what “complete insulin independence” means in the context of type 2 diabetes management. For the majority of patients with long-standing type 2 diabetes, the clinical goal is disease management — controlling blood glucose, reducing HbA1c, and slowing the progression of complications. Achieving complete insulin independence — meaning the patient no longer requires exogenous insulin therapy to maintain glycemic control — has historically been considered either impossible or achievable only through bariatric surgery in selected patients.

The mechanisms by which retatrutide achieves this outcome involve:

• Dramatic reduction in peripheral insulin resistance through weight loss-mediated improvement in skeletal muscle GLUT4 expression and adipose tissue inflammation
• Relief of glucolipotoxicity in pancreatic beta cells — the pathological state in which chronically elevated glucose and lipid levels progressively impair beta cell function and survival. As retatrutide corrects systemic metabolic dysfunction, beta cells can recover.
• Reduction in hepatic glucose output through both GLP-1R-mediated glucagon suppression and GCGR-mediated modulation of hepatic metabolic flux
• Restoration of incretin sensitivity — patients with type 2 diabetes have blunted incretin responses; pharmacological receptor agonism bypasses this impairment.
• Potential direct effects on pancreatic beta cell regeneration — GLP-1R agonism has been demonstrated in preclinical models to stimulate beta cell neogenesis and reduce apoptosis. However, the extent of this effect in humans remains an active area of investigation.

The fact that one in three type 2 diabetes patients treated with retatrutide achieved complete insulin independence is not merely a clinical milestone — it is a paradigm shift. It demonstrates that type 2 diabetes is not the irreversible, inevitably progressive disease that conventional medicine has long assumed it to be when addressed at the upstream level with sufficient pharmacological potency.

NASH Resolution and Fibrosis Regression: The Lancet Gastroenterology 2024

The 2024 Lancet Gastroenterology publication on retatrutide’s effects in non-alcoholic steatohepatitis (NASH) is equally striking (Loomba et al., 2024). The data showed that retatrutide resolved NASH—defined by the composite endpoint of NASH resolution without worsening of fibrosis—in 62% of subjects, with a remarkable additional finding: fibrosis regression in a substantial proportion of patients.

Fibrosis regression in NASH is significant because hepatic fibrosis was long considered an irreversible endpoint of liver disease progression. Fibrosis — the accumulation of collagen and extracellular matrix proteins driven by activated hepatic stellate cells — represents the bridge between reversible steatohepatitis and irreversible cirrhosis. The demonstration that retatrutide can not only halt fibrosis progression but actually reverse established fibrosis challenges this longstanding assumption and has profound implications for the management of what is projected to become the leading cause of liver transplantation in the United States.

The mechanisms by which retatrutide achieves NASH resolution and fibrosis regression include:

• Glucagon receptor-mediated enhancement of hepatic beta-oxidation: By driving the liver to oxidize its stored triglycerides as fuel, retatrutide depletes the hepatic lipid accumulation that is the primary driver of lipotoxicity and hepatic inflammation in NASH
• Reduction in hepatic de novo lipogenesis: The combined insulin-sensitizing effects of retatrutide reduce the hepatic lipogenic signaling that drives fat accumulation in the first place
• GLP-1R-mediated anti-inflammatory effects: Direct GLP-1R activation on hepatic Kupffer cells (resident liver macrophages) suppresses the production of pro-inflammatory cytokines that drive the progression from simple steatosis to steatohepatitis
• Weight loss-associated reduction in visceral adipose tissue inflammation: As visceral fat depots shrink, the flux of free fatty acids and pro-inflammatory adipokines to the liver via the portal circulation decreases, reducing the inflammatory burden on hepatocytes
• Potential direct effects on hepatic stellate cell activation: Emerging preclinical evidence suggests that GLP-1R agonism may directly suppress hepatic stellate cell activation, reducing fibrogenic signaling independent of the metabolic effects

The 62% NASH resolution rate achieved by retatrutide compares extraordinarily favorably with results from all previously tested pharmaceutical agents for NASH, most of which have failed to meet primary endpoints in Phase 3 trials. This makes retatrutide the most clinically effective medical intervention for NASH ever documented in human clinical trials.

The Economics of Upstream Correction: Pharmaceutical Revenue Architecture and Metabolic Disease

The Revenue Architecture Built on Insulin Resistance

To understand the full scope of what retatrutide represents—and why its broad accessibility faces significant resistance—it is essential to examine the economic architecture built around the downstream consequences of insulin resistance and metabolic disease.

The pharmaceutical treatment of insulin resistance’s downstream consequences is organized into distinct, profitable therapeutic categories, each with its own drug portfolio, clinical specialty, and revenue stream:

Endocrinology and Diabetes Management

• Eli Lilly’s insulin portfolio — including insulin lispro (Humalog), insulin degludec/lispro (Lyumjev), and related insulin formulations — generated approximately $3.1 billion in revenue in 2023
• The global antidiabetic drug market, encompassing insulins, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and biguanides, represents one of the largest pharmaceutical market segments in the world.
• Diabetes management requires ongoing, indefinite pharmaceutical intervention — patients typically progress from oral monotherapy to combination oral therapy to injectable therapy to insulin over a period of years, generating escalating pharmaceutical revenue at each stage.

Hepatology: The NAFLD/NASH Market

• Leading financial analysts projected the NAFLD/NASH pharmaceutical market to reach approximately $35 billion annually by 2027, driven by the enormous unmet need for effective pharmacological treatment of a disease affecting an estimated 25-30% of the global adult population.
• Before the retatrutide data, no pharmaceutical agent had achieved regulatory approval for NASH in the United States, making it one of the most actively pursued targets in pharmaceutical development.
• The pipeline for NASH therapeutics included dozens of compounds across multiple mechanisms of action, representing billions of dollars in research investment predicated on NASH remaining a large, inadequately treated patient population.

Oncology

• Obesity-related cancers — including the colorectal, breast, endometrial, and other cancer types linked to hyperinsulinemia — represent a significant portion of the $200+ billion global oncology market.
• The American Cancer Society’s finding that 40% of American cancers are obesity-related means that a substantial fraction of the global cancer treatment revenue is downstream of metabolic dysfunction.
• Cancer treatment costs per patient can reach hundreds of thousands of dollars over the course of treatment, making oncology among the highest-revenue therapeutic areas in medicine.

Cardiology and Hypertension

• Cardiovascular disease — with insulin resistance, dyslipidemia, hypertension, and endothelial dysfunction as primary upstream drivers — represents the largest single therapeutic category in global pharmaceutical spending.
• Statins, antihypertensives, antiplatelets, anticoagulants, and heart failure medications collectively generate hundreds of billions of dollars in annual global pharmaceutical revenue.

Gastroenterology

• GERD, irritable bowel syndrome, and other gastrointestinal conditions are disproportionately prevalent in patients with metabolic syndrome and obesity, generating a substantial gastroenterology pharmaceutical market
• Proton pump inhibitors (PPIs) alone represent a multi-billion-dollar global market, with obesity and metabolic dysfunction as major drivers of GERD incidence.

The Strategic Calculation: Why Broad Access Threatens the Revenue Architecture

The economic logic behind resistance to broad access to retatrutide is, at its most reductive, a straightforward calculation: if you correct the upstream problem, you reduce demand for downstream solutions.

Consider the following scenario, framed in terms of population-level impact:

The CDC’s 2023 data document that 42.4% of American adults are obese. The American Diabetes Association’s 2024 data document that 136 million Americans have diabetes or prediabetes. 88 million Americans meet the diagnostic criteria for metabolic syndrome — the clinical constellation of central obesity, insulin resistance, hypertension, dyslipidemia, and elevated fasting glucose that represents the clearest clinical marker of the upstream hyperinsulinemic state.

If retatrutide were deployed at accessible pricing — a figure discussed in the context of sustainable public health economics — across a substantial proportion of the 88 million Americans with metabolic syndrome:

• A significant fraction would achieve the degree of metabolic improvement documented in clinical trials — insulin independence, NASH resolution, substantial weight loss, blood pressure normalization, and lipid improvement
• The patient population requiring ongoing pharmaceutical management for type 2 diabetes would contract substantially
• The patient population that would otherwise progress to NASH and requires NASH-specific pharmaceutical intervention would decrease dramatically.
• The incidence of obesity-related cancers would decline, reducing long-term oncology treatment volume.
• Cardiovascular event rates would decrease, reducing the long-term demand for cardiovascular intervention and management.

Each of these downstream contractions would reduce pharmaceutical revenue across multiple therapeutic categories. Critically, these revenue reductions would concentrate in the most profitable, highest-volume segments of the pharmaceutical market. These chronic disease management categories generate reliable, recurring revenue because the underlying metabolic dysfunction is never corrected at its source.

The Market Control Architecture: Exclusivity, Classification, and Access Limitation

The discussion of why retatrutide’s broad accessibility is constrained requires understanding the regulatory and intellectual property architecture that governs pharmaceutical market control in the United States:

Biologic Classification

Retatrutide is classified as a biologic — a large-molecule, peptide-based therapeutic agent — rather than a small-molecule drug. This classification has profound implications for market exclusivity, because biologics receive 12 years of regulatory exclusivity under the Biologics Price Competition and Innovation Act (BPCIA) — compared to the 5 years of exclusivity available to new chemical entities and the 3 years available to new formulations of existing drugs under the Hatch-Waxman Act.

This 12-year exclusivity period means no biosimilar (the biologic equivalent of a generic drug) can enter the market until 12 years after the reference biologic’s initial approval, regardless of the compound’s patent status. During this period, the originator company maintains complete pricing control.

Compounding Prohibition

The FDA’s Section 503B outsourcing facility framework and broader drug compounding regulations under the Federal Food, Drug, and Cosmetic Act allow licensed compounding pharmacies to produce copies of pharmaceutical agents on the FDA’s drug shortage list. While semaglutide was on the shortage list, licensed compounding pharmacies were legally permitted to compound it, which dramatically expanded patient access at a significantly lower cost.

As drug manufacturers resolve supply shortages and formally petition the FDA to remove compounds from the shortage list, the legal basis for compounding is eliminated, and compounding pharmacies are prohibited from continuing to produce the compound. This process — which Eli Lilly has actively pursued with respect to its GLP-1/GIP portfolio — effectively removes the lower-cost access pathway while the originator drug remains priced for maximum revenue extraction.

API Supplier Litigation

The active pharmaceutical ingredient (API) supply chain for peptide-based therapeutics like retatrutide involves a small number of specialized synthesis facilities capable of producing the complex peptide chemistry involved. Originator manufacturers have pursued legal strategies targeting API suppliers that provide raw materials to compounding pharmacies, creating additional upstream constraints on the compounding pathway.

The Pricing Architecture

At a controlled retail price point of approximately $ 40 billion, as discussed in financial analyst projections.

The critical strategic insight is that this pricing and access architecture is designed to maximize revenue from the narrowest clinically indicated patient population — those with the most severe disease burden, the greatest payer coverage, and the highest willingness to pay — while avoiding the broad deployment that would generate sufficient metabolic improvement at the population level to reduce downstream pharmaceutical demand.

This is not a conspiracy theory. It is a straightforward application of portfolio revenue optimization — the same strategic logic that governs pricing decisions in every large pharmaceutical company. The executives who make these decisions are not motivated by malice; they are motivated by fiduciary responsibility to shareholders. But the consequence — that a molecule capable of dramatically reducing the burden of chronic metabolic disease is deliberately restricted to a narrow, high-revenue patient segment — has profound public health implications.

Transform Your Body!- Video

The Burden of Metabolic Disease: Real People, Real Consequences

The Scale of the Metabolic Disease Epidemic in the United States

It is easy to become desensitized to epidemiological statistics. But behind each of these numbers is a human being — a patient, a family member, a neighbor — whose quality of life, longevity, and medical burden are shaped by the upstream metabolic dysfunction we are discussing. Let me ground this discussion in the real-world scale of what we are dealing with:

• 4% of American adults are obese (CDC, 2023) — representing approximately 110 million people living with a condition that significantly elevates their risk for all eleven of the insulin resistance-driven chronic diseases discussed above
• 136 million Americans have diabetes or pre-diabetes (ADA, 2024) — a number that represents more than 40% of the entire adult population of the United States
• 40% of American cancers are obesity-related (American Cancer Society, 2023) — meaning that if the metabolic epidemic were corrected, the cancer incidence rate in the United States would potentially decline by nearly half
• 55 million people worldwide are living with dementia (World Health Organization, 2023), with Alzheimer’s disease — increasingly recognized as being driven by brain insulin resistance — representing the most common form; and these numbers are projected to nearly triple to 153 million by 2050 if the underlying metabolic epidemic is not addressed

Each of these statistics represents not only human suffering but also enormous economic costs—to individuals, families, employers, insurance systems, and governments. The total economic burden of obesity alone in the United States has been estimated at $173 billion annually in direct medical costs (Cawley et al., 2021). When indirect costs including lost productivity, disability, and premature mortality are included, the total economic impact is substantially larger.

Metabolic Dysfunction as the Primary Upstream Driver of Neurodegeneration

The relationship between insulin resistance and neurodegeneration — particularly Alzheimer’s disease — deserves special attention because it is one of the most rapidly evolving areas of metabolic medicine and one of the most consequential for an aging global population.

Alzheimer’s disease as “Type 3 Diabetes”

The concept of “Type 3 Diabetes” — first proposed by Suzanne de la Monte and Jack Wands in their landmark 2005 publication in the Journal of Alzheimer’s Disease — describes the pattern of brain insulin resistance that is increasingly recognized as a central feature of Alzheimer’s disease pathology (de la Monte & Wands, 2005). The mechanistic basis for this relationship involves:

• Impaired neuronal glucose metabolism: Neurons — particularly in the hippocampus, entorhinal cortex, and parietal lobes — are dependent on insulin signaling for efficient glucose uptake and mitochondrial energy production. When brain insulin resistance develops, neurons progressively lose their capacity to utilize glucose as an energy substrate, leading to the hypometabolic state that is one of the earliest detectable markers of Alzheimer’s disease on FDG-PET neuroimaging.
• Impaired amyloid-beta clearance: Normal insulin receptor signaling in neurons drives expression of insulin-degrading enzyme (IDE), one of the primary proteolytic enzymes responsible for clearing amyloid-beta peptides. Brain insulin resistance reduces IDE expression and activity, allowing amyloid-beta to accumulate and aggregate into the plaques that are a pathological hallmark of Alzheimer’s disease.
• Tau hyperphosphorylation: The Akt pathway downstream of the insulin receptor normally phosphorylates and inactivates glycogen synthase kinase-3 beta (GSK-3beta), the primary kinase responsible for pathological tau phosphorylation. Brain insulin resistance, by reducing Akt activity, releases GSK-3beta from inhibition and promotes the tau hyperphosphorylation that leads to neurofibrillary tangle formation.
• Neuroinflammation: Systemic hyperinsulinemia and the associated chronic low-grade inflammation activate microglial cells — the brain’s resident immune cells — and promote a pro-inflammatory neurological milieu that accelerates neuronal injury and synaptic dysfunction

The implications of this mechanistic understanding are profound: preventing or correcting systemic insulin resistance may represent one of the most effective strategies for reducing the risk of Alzheimer’s disease. Emerging evidence on GLP-1R agonist effects in neurodegeneration—including data suggesting GLP-1R agonists may slow cognitive decline and reduce amyloid accumulation—suggests that triple agonists like retatrutide may offer neuroprotective benefits beyond their metabolic effects.

Integrative Chiropractic Care and Functional Medicine in Metabolic Disease Management

Why Chiropractic Care Belongs in the Metabolic Disease Conversation

At this point in the discussion, some readers may be wondering: what does chiropractic care have to do with insulin resistance, retatrutide, and metabolic disease? The answer is both more profound and more evidence-based than conventional assumptions might suggest.

My approach to chiropractic care at Injury Medical Clinic PA is grounded in the understanding that the neuromusculoskeletal system — which is the primary domain of chiropractic practice — does not exist in isolation from the metabolic and endocrine systems. The body is an integrated biological system, and the relationships between spinal function, nervous system regulation, physical activity capacity, and metabolic health are bidirectional and clinically significant.

The Nervous System, Autonomic Regulation, and Metabolic Homeostasis

The autonomic nervous system (ANS) — with its sympathetic and parasympathetic divisions — plays a critical regulatory role in metabolic homeostasis. Chronic sympathetic nervous system (SNS) activation — which is associated with chronic pain, psychological stress, sleep disruption, and sedentary behavior — has been demonstrated to:

• Increase insulin resistance through cortisol- and catecholamine-mediated interference with insulin signaling
• Drive visceral adiposity by promoting preferential fat deposition in visceral depots through beta-3 adrenergic receptor activation.
• Elevate blood pressure through RAAS activation and direct vasoconstriction
• Suppress parasympathetic tone, reducing the vagal nerve’s anti-inflammatory signaling and impairing the gut-brain axis communication that regulates appetite and insulin secretion

Spinal manipulation therapy (SMT) — the primary manual therapy technique used in chiropractic care — has been demonstrated in multiple studies to reduce markers of sympathetic hyperactivation and improve heart rate variability (HRV), a validated measure of autonomic nervous system balance (Budgell & Polus, 2006). By reducing SNS dominance and improving parasympathetic tone, chiropractic care creates a neurological environment that is more conducive to metabolic healing.

This is not merely theoretical. The hypothalamic-pituitary-adrenal (HPA) axis — which governs the stress hormone response — is directly influenced by afferent signals arising from the spine and paraspinal musculature. When spinal joint dysfunction (subluxation) generates aberrant afferent nociceptive input into the brainstem and hypothalamus, it contributes to chronic HPA axis activation and the resulting cortisol-mediated metabolic dysfunction. Correcting spinal dysfunction through chiropractic manipulation reduces this aberrant afferent input and may help normalize HPA axis activity.

Physical Function, Exercise Capacity, and Insulin Sensitivity

One of the most powerful non-pharmacological interventions for improving insulin sensitivity is regular physical activity — particularly resistance training and high-intensity interval training (HIIT), both of which drive GLUT4 expression and translocation in skeletal muscle through AMP-activated protein kinase (AMPK) signaling.

However, physical activity-based metabolic interventions are only accessible to patients who are physically capable of exercising. Patients with chronic musculoskeletal pain — including neck pain, low back pain, hip pain, knee pain, and shoulder pain — are significantly limited in their ability to engage in the therapeutic exercise that is essential for insulin sensitivity improvement.

By reducing musculoskeletal pain, restoring joint range of motion, and improving functional movement patterns, chiropractic care plays a critical role in restoring the patient’s capacity to engage in metabolically therapeutic physical activity. In this sense, chiropractic care is not merely a symptomatic intervention—it enables the lifestyle modification that underpins metabolic disease management.

At Injury Medical Clinic PA, we recognize this relationship explicitly. My clinical approach integrates chiropractic manipulation with therapeutic exercise prescription, functional movement assessment, and rehabilitation protocols designed to progressively restore physical function and enable the level of physical activity that drives meaningful improvements in insulin sensitivity.

Chronic Pain, Inflammation, and the Metabolic Consequence

Chronic musculoskeletal pain is not metabolically neutral. Pain drives:

• Chronic cortisol elevation through HPA axis activation, which promotes insulin resistance, visceral fat accumulation, and muscle catabolism
• Physical inactivity, which reduces skeletal muscle GLUT4 expression and AMPK signaling, worsening insulin resistance
• Sleep disruption — pain is among the most common causes of insomnia and poor sleep quality, and sleep restriction is independently associated with increased insulin resistance, elevated ghrelin, reduced leptin, and greater caloric intake.
• Psychological stress and depression, both of which further activate the HPA axis and contribute to behaviors (emotional eating, sedentary behavior) that worsen metabolic dysfunction

Effective management of chronic musculoskeletal pain through chiropractic care therefore has direct metabolic benefits — not because chiropractic care directly modulates insulin signaling, but because it addresses one of the most significant drivers of the behavioral and neuroendocrine dysfunction that perpetuates metabolic disease.

Functional Medicine: Addressing the Root Causes of Metabolic Dysfunction

My training and certification in functional medicine—reflected in my CFMP and IFMCP credentials—provide the framework through which I approach metabolic disease management at the root-cause level. Functional medicine is a systems-biology-based clinical approach that identifies and addresses the upstream drivers of chronic disease rather than simply managing downstream symptoms.

In the context of metabolic disease, the functional medicine framework leads me to assess and address the following domains in every patient:

Nutritional Assessment and Therapeutic Diet

Diet is the single most powerful modifiable driver of insulin resistance. The functional medicine approach to nutrition for metabolic disease management goes far beyond the generic “eat less and move more” advice that characterizes conventional dietary counseling. It involves a detailed, individualized assessment of:

• Glycemic load and glycemic index of the patient’s habitual diet, with specific targeting of high-glycemic-load carbohydrate sources that drive postprandial hyperinsulinemia
• Refined sugar and fructose consumption — dietary fructose, in particular, is uniquely lipogenic at the liver and drives hepatic de novo lipogenesis and visceral fat accumulation through mechanisms that are partially independent of caloric intake
• Dietary fat composition — the ratio of saturated, monounsaturated, and polyunsaturated fatty acids in the diet significantly influences membrane fluidity, insulin receptor sensitivity, and inflammatory signaling
• Protein quality and quantity — adequate dietary protein supports muscle mass preservation during caloric restriction, which is essential for maintaining resting metabolic rate and skeletal muscle GLUT4 expression
• Micronutrient status — deficiencies in magnesium, chromium, zinc, vitamin D, and B vitamins are disproportionately prevalent in patients with insulin resistance and metabolic syndrome, and each of these micronutrients plays specific roles in insulin signaling and glucose metabolism

Therapeutic dietary approaches I employ in metabolic disease management include:

• Time-restricted eating (TRE) / intermittent fasting — reducing the feeding window to 8-10 hours per day improves insulin sensitivity through multiple mechanisms, including reduced postprandial insulin area under the curve, improved mitochondrial biogenesis, and activation of cellular autophagy
• Low-carbohydrate and ketogenic dietary protocols—dramatically reducing dietary carbohydrate lower postprandial glucose and insulin excursions, reduce triglycerides, and may directly improve NAFLD by reducing hepatic de novo lipogenesis.
• Mediterranean dietary pattern — emphasizing olive oil, fatty fish, legumes, vegetables, and whole grains as the primary carbohydrate source — is associated with improved insulin sensitivity, reduced cardiovascular risk, and lower cancer incidence in multiple large prospective studies
• Elimination protocols targeting food sensitivities — chronic gut-mediated immune activation from food antigens can perpetuate systemic inflammation that contributes to insulin resistance through cytokine-mediated interference with insulin signaling

Gut Microbiome and the Metabolic Connection

The gut microbiome — the community of approximately 38 trillion microorganisms inhabiting the human gastrointestinal tract — plays a critically important and increasingly well-understood role in metabolic regulation. Specific features of gut microbiome composition have been linked to insulin resistance, obesity, and metabolic syndrome:

• Reduced microbial diversity — patients with obesity and insulin resistance consistently demonstrate lower gut microbial diversity compared to metabolically healthy individuals, with reduced representation of beneficial species including Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacterium species
• Elevated Firmicutes-to-Bacteroidetes ratio — this taxonomic imbalance has been associated with greater caloric extraction from dietary fiber and increased short-chain fatty acid production patterns that favor lipid synthesis over fatty acid oxidation
• Increased intestinal permeability (“leaky gut”) — dysbiosis-associated disruption of tight junction proteins in the intestinal epithelium allows bacterial lipopolysaccharide (LPS) — a component of Gram-negative bacterial cell walls — to translocate into the portal circulation, driving systemic endotoxemia and activating TLR-4-mediated inflammatory signaling that interferes with insulin signaling through the IRS-1/PI3K pathway
• Altered bile acid metabolism — the gut microbiome plays a central role in secondary bile acid production, and bile acids function as metabolic signaling molecules acting through farnesoid X receptor (FXR) and TGR-5 receptors that regulate glucose and lipid metabolism

In my functional medicine practice, I address the gut microbiome through targeted interventions including:

• Probiotic therapy with specific, evidence-based strains relevant to metabolic outcomes
• Prebiotic fiber supplementation to nourish beneficial bacterial populations
• Elimination of dietary factors that disrupt the microbiome, including excessive refined sugar, artificial sweeteners, and excess dietary fat
• Herbal antimicrobial protocols where evidence of pathogenic overgrowth exists
• Assessment and treatment of small intestinal bacterial overgrowth (SIBO), which is disproportionately prevalent in patients with metabolic syndrome and may contribute to systemic endotoxemia

Comprehensive Hormonal Assessment

Metabolic dysfunction does not occur in a hormonal vacuum. In my functional medicine practice, I conduct comprehensive hormonal assessments that go beyond the standard thyroid and HbA1c tests typically ordered in conventional medicine:

• Full thyroid panel including TSH, free T4, free T3, reverse T3, and thyroid antibodies — because hypothyroidism and Hashimoto’s thyroiditis are disproportionately prevalent in patients with metabolic syndrome and can significantly impair metabolic rate and glucose disposal
• Adrenal function assessment including morning cortisol, DHEA-S, and where indicated, a four-point salivary cortisol profile — because HPA axis dysregulation drives visceral fat accumulation and insulin resistance
• Sex hormone assessment including testosterone (total and free), estradiol, progesterone, and SHBG — because testosterone deficiency in men is associated with insulin resistance, and estrogen imbalance in women contributes to metabolic dysfunction.
• Comprehensive insulin resistance markers beyond HbA1c — including fasting insulin, HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), oral glucose tolerance test with insulin levels, and where available, continuous glucose monitoring (CGM) data
• Advanced lipid fractionation — because the standard LDL-C measurement dramatically underestimates cardiovascular risk in patients with insulin resistance; advanced panels including LDL particle number, small dense LDL, lipoprotein(a), and apolipoprotein B provide a much more accurate cardiovascular risk assessment
• Inflammatory markers including high-sensitivity CRP, IL-6, and fibrinogen — which provide insight into the degree of systemic inflammation driving and driven by metabolic dysfunction

Sleep Medicine and Circadian Biology

As noted above, sleep quality and duration are critically important modulators of metabolic health. In my functional medicine practice, I give sleep assessment the clinical weight it deserves — which conventional medicine frequently does not.

• Obstructive sleep apnea (OSA) — I screen all metabolically compromised patients for OSA, which is both a consequence of metabolic syndrome and an independent driver of insulin resistance through intermittent hypoxia-mediated activation of the HPA axis and sympathetic nervous system. Untreated OSA dramatically impairs the metabolic benefits of dietary and pharmacological interventions.
• Circadian rhythm disruption—shift work, late-night eating, excessive blue light exposure, and irregular sleep schedules—disrupts the normal circadian regulation of insulin sensitivity, which is highest in the morning and progressively decreases through the afternoon and evening. Patients who eat most of their calories in the evening—a pattern that is extremely common in modern societies—consume food when insulin sensitivity is at its nadir, dramatically increasing postprandial insulin requirements.
• Sleep architecture optimization — I address specific disruptions to sleep architecture, including inadequate slow-wave sleep (the most metabolically restorative sleep stage) and REM disruption, through behavioral, nutritional, and, where appropriate, supplementation interventions.

The Multidisciplinary Integrative Care Model at Injury Medical Clinic PA

Dr. Maria Guadalupe Cardenas, MD: Medical Director and Collaborative Physician

At Injury Medical Clinic PA — also known as Mission Plaza Injury Medical Clinic — in El Paso, Texas, I have the privilege of working alongside one of the region’s most experienced and respected internists: Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933).

Dr. Cardenas is board-certified in Internal Medicine and brings over 40 years of clinical experience as an internist to our collaborative practice. Her breadth and depth of experience span the full spectrum of internal medicine—including the management of diabetes, cardiovascular disease, hypertension, thyroid disorders, kidney disease, and complex multisystem illness—making her the ideal collaborative physician for the integrative, metabolic-focused care model we practice together.

In our multidisciplinary setup — which represents the gold standard model for integrative and injury care clinics — Dr. Cardenas serves as Medical Director and Collaborative Physician, providing:

• Medical oversight and direction for the clinical protocols employed across our practice
• Internal medicine evaluation and management for patients with complex metabolic comorbidities requiring the expertise of a board-certified internist
• Medication management and prescription authority for pharmaceutical interventions — including emerging metabolic therapies — that fall within the scope of internal medicine practice
• Regulatory compliance and clinical quality assurance, ensuring that all care delivered at our practice meets the highest standards of evidence-based medical practice
• Collaborative clinical decision-making with me regarding patient care plans that integrate chiropractic, functional medicine, and internal medicine perspectives.

The model in which a Doctor of Chiropractic and an MD with Internal Medicine board certification practice collaboratively under one roof is powerful precisely because it brings together complementary clinical competencies that individually address different dimensions of the patient’s health. Dr. Cardenas’s internal medicine expertise ensures the medical dimensions of our patients’ care—particularly managing complex metabolic comorbidities—receive the full benefit of board-certified medical oversight. My expertise in chiropractic care, functional medicine, neuromusculoskeletal medicine, and the advanced practice registered nursing scope (reflected in my APRN, FNP-BC credentials) addresses the dimensions of care that fall within those disciplines.

Together, our team provides integrative care that is genuinely greater than the sum of its parts.

The Scope of Services at Injury Medical Clinic PA

Our practice’s integrative, multidisciplinary model encompasses the following clinical service areas:

Chiropractic Care and Spinal Manipulation Therapy

At the core of my clinical practice is evidence-based chiropractic care, including:

• Spinal manipulation therapy (SMT) using diversified, Gonstead, activator, and Cox flexion-distraction techniques, selected and individualized based on the patient’s presentation, imaging findings, and clinical assessment
• Extremity manipulation and mobilization for peripheral joint dysfunction affecting the shoulders, hips, knees, ankles, and upper extremities
• Myofascial release and soft tissue therapy targeting hypertonic muscles, fascial restrictions, and trigger points that contribute to pain and functional limitation
• Instrument-assisted soft tissue mobilization (IASTM) for the management of scar tissue, fascial adhesions, and tendinopathies
• Kinesiotaping and functional bracing as adjunctive support for injured or unstable joints during the rehabilitation process

We select chiropractic techniques at our clinic based on the current evidence base. I am committed to evidence-based chiropractic care—meaning clinical decision-making is informed by the best available research evidence, integrated with my clinical expertise and the patient’s values and preferences.

Functional Medicine and Metabolic Assessment

As described in detail above, my functional medicine approach addresses the root causes of metabolic dysfunction through:

• Comprehensive metabolic evaluation including advanced laboratory testing for insulin resistance markers, hormonal dysfunction, gut health, nutritional status, and inflammatory burden
• Individualized therapeutic diet prescription tailored to the patient’s metabolic phenotype, food preferences, and clinical goals
• Evidence-based supplementation protocols targeting specific metabolic dysfunctions identified through functional laboratory testing
• Lifestyle medicine interventions addressing sleep, stress management, physical activity, and circadian rhythm optimization
• Ongoing monitoring and adjustment of metabolic interventions using quantitative biomarkers — including CGM data, fasting insulin, HOMA-IR, advanced lipid panels, and inflammatory markers — to objectively track progress and refine the treatment approach

Internal Medicine and Medical Management (Dr. Cardenas)

Under Dr. Cardenas’s medical direction and collaborative oversight, our practice provides:

• Internal medicine evaluation and management for patients with metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia, NAFLD/NASH, and related conditions
• Pharmaceutical management of metabolic conditions, including consideration of emerging therapies such as GLP-1R agonists and, as they become clinically available and appropriately indicated, triple agonist therapy
• Coordination of specialty referrals where indicated — including endocrinology, hepatology, cardiology, and oncology — ensuring that our patients receive comprehensive, coordinated care across all relevant specialties
• Management of acute illness and intercurrent medical conditions that arise in the context of our patients’ ongoing chronic disease management

Personal Injury Care and Rehabilitation

A significant component of our practice involves managing personal injury cases—particularly motor vehicle accident (MVA) injuries, workplace injuries, and slip-and-fall injuries. Our personal injury care services include:

• Comprehensive injury evaluation and documentation — including detailed neurological and musculoskeletal examination, review of diagnostic imaging, and preparation of clinical documentation appropriate for personal injury legal proceedings
• Evidence-based injury rehabilitation — including therapeutic exercise, neuromuscular re-education, proprioceptive training, and progressive functional restoration
• Pain management — using a multimodal approach that integrates chiropractic manipulation, physical rehabilitation, soft tissue therapy, and where medically indicated, medication management under Dr. Cardenas’s oversight
• MRI and advanced imaging interpretation — I hold training and certification in advanced imaging interpretation (ATN credential) and work with radiological consultation to ensure that structural injuries are accurately identified and appropriately managed
• Coordination with legal and insurance stakeholders — including preparation of narrative reports, letters of protection, and expert documentation required in personal injury cases

Electrodiagnostic Medicine and Neurological Assessment

My CCST (Certified Chiropractic Sports Physician Training) background, combined with my APRN/FNP-BC credentials and clinical training, enables our practice to offer:

• Electrodiagnostic studies including electromyography (EMG) and nerve conduction velocity (NCV) studies for the assessment of peripheral nerve injuries, radiculopathies, and neuromuscular conditions — which are commonly encountered in personal injury and sports medicine contexts
• Comprehensive neurological examination and coordination with neurology consultation for complex neurological presentations
• Sports medicine and performance optimization — drawing on my sports chiropractic training to provide injury management and performance enhancement services to athletic patients

The Clinical Philosophy Behind Our Integrative Approach

Evidence-Based Practice as the Foundation

Everything we do at Injury Medical Clinic PA is grounded in the best available scientific evidence. I want to be explicit about this because the integrative medicine space is unfortunately populated by practitioners who make claims not supported by evidence. My approach — and our entire clinical team’s approach — is to apply modern, evidence-based research to clinical decision-making in a rigorous, transparent, and patient-centered way.

This means:

• We do not use treatments that lack a plausible mechanistic basis or an adequate evidence base
• We acknowledge the limitations of current evidence where they exist, and we communicate those limitations honestly to patients.
• We continuously update our clinical knowledge by engaging with the peer-reviewed literature, attending academic conferences, and participating in continuing education.
• We measure outcomes quantitatively — using validated clinical assessments, laboratory biomarkers, and patient-reported outcome measures — to objectively evaluate the effectiveness of our interventions.
• We engage in shared decision-making with patients, ensuring treatment plans integrate the best available evidence, our clinical expertise, and each patient’s values and preferences.

The Upstream-First Clinical Philosophy

Our clinical philosophy is organized around the principle that upstream problems require upstream solutions. The conventional medical model — which is predominantly oriented toward the management of downstream disease manifestations — generates enormous expenditure of resources, significant iatrogenic risk from polypharmacy and procedural intervention, and largely unsatisfying clinical outcomes for patients with chronic metabolic disease.

Our approach, in contrast, begins with the question: What is the upstream driver of this patient’s condition? And then: What interventions, applied at the upstream level, will produce the greatest downstream benefit?

This philosophy is directly aligned with the scientific evidence on retatrutide and the broader incretin medicine revolution. The clinical data on retatrutide compellingly show that addressing upstream metabolic dysfunction—correcting insulin resistance, reducing visceral adiposity, normalizing incretin signaling—resolves multiple downstream conditions simultaneously. NASH resolves. Glycemic control normalizes to the point of insulin independence. Blood pressure improves. Cardiovascular risk markers normalize.

This is exactly what we see in our clinical practice when we apply a rigorous, comprehensive, upstream-focused functional medicine and integrative care approach to metabolic disease. Patients who engage fully with our program — addressing nutrition, sleep, stress, physical activity, gut health, hormonal optimization, and where indicated, pharmacological support — experience improvements across multiple systems simultaneously, because all of those systems were suffering from the same upstream metabolic dysfunction.

The Patient-Centered Care Commitment

At Injury Medical Clinic PA, our commitment to genuine patient-centered care is not a marketing slogan. It is a clinical and ethical imperative that shapes every aspect of how we practice.

Patient-centered care means:

• Taking the time to understand each patient’s full health history, including the environmental, behavioral, and psychosocial factors that have shaped their metabolic health
• Explaining our findings and treatment recommendations in language that patients can understand, so that they can make genuinely informed decisions about their care
• Respecting each patient’s autonomy — we provide our best clinical recommendations. Still, we recognize that patients have the right to make decisions about their own health that align with their own values, preferences, and life circumstances.
• Being honest about what we know and what we do not know — the metabolic medicine space is evolving rapidly, and intellectual honesty about the limits of current evidence is an expression of respect for our patients
• Advocating for our patients’ access to the most effective available treatments — including emerging pharmacological therapies like retatrutide — even when that advocacy requires navigating insurance, regulatory, and financial barriers.

The advocacy dimension of patient-centered care is directly relevant to the broader discussion in this post. The debate about retatrutide’s accessibility is not an abstract policy discussion — it is a question about whether our patients, right now, in 2026, can access a treatment that has demonstrated the capacity to resolve NASH, achieve insulin independence, and dramatically reduce metabolic risk in the clinical trial setting.

At our practice, we take that question seriously and work actively to identify every available pathway through which patients who may benefit from emerging metabolic therapies can access them.

The Physiological Depth of Triple Agonism: Why Retatrutide Represents a Qualitative Leap

Understanding the Incretin System in Full Biological Context

To fully appreciate why retatrutide represents such a significant advance in metabolic medicine, it helps to understand the incretin system in its full physiological context — not merely as a pharmacological target, but as a beautifully integrated biological communication network that links the gut, the pancreas, the liver, the brain, and the adipose tissue in a coordinated metabolic regulatory system.

The incretin effect refers to the observation that oral glucose administration produces a significantly greater insulin secretory response than intravenous glucose administration, which produces identical blood glucose levels. This difference — attributed to the gut-derived incretin hormones GLP-1 and GIP — accounts for approximately 50-70% of the insulin response to a typical meal in healthy individuals. In patients with type 2 diabetes, the incretin effect is severely blunted — which means that a very large proportion of the impaired postprandial insulin response in type 2 diabetes is attributable to dysfunction in the gut-pancreas hormonal axis, not simply to intrinsic beta cell failure.

This insight has profound clinical implications: if we can pharmacologically restore the incretin signal — bypassing the impaired endogenous GLP-1 and GIP response — we can potentially restore a large fraction of the normal postprandial insulin response and thereby dramatically improve glycemic control without requiring the pancreatic beta cells to produce more insulin than they are capable of producing.

This is exactly what GLP-1 receptor agonists do. And this is what triple agonism does with even greater potency and breadth.

The Hepatic Axis: Why Glucagon Receptor Agonism Is the Key to NASH Resolution

The liver is the body’s metabolic hub —the organ through which virtually all absorbed nutrients pass via the portal circulation before reaching systemic circulation. In the context of insulin resistance and hyperinsulinemia, the liver becomes the site of several converging pathological processes:

1. Elevated Hepatic de Novo Lipogenesis (DNL)

Insulin is the primary driver of hepatic DNL — the synthesis of fatty acids from non-lipid precursors, primarily excess carbohydrate (glucose and fructose). In the insulin-resistant state, a paradox emerges: while the insulin signaling pathway driving glucose uptake (the PI3K/Akt/GLUT4 pathway) becomes impaired, the pathway driving lipid synthesis (SREBP-1c activation) remains sensitive to insulin, even at pathologically elevated levels.

This phenomenon — sometimes called “selective insulin resistance” — means that hyperinsulinemia drives relentless hepatic DNL even as it fails to stimulate glucose disposal adequately. The result is progressive hepatic triglyceride accumulation — non-alcoholic fatty liver disease — which, when combined with oxidative stress and inflammation, progresses to steatohepatitis.

2. Impaired Hepatic Beta-Oxidation

Under normal conditions, fasting states and periods of energy deficit activate hepatic peroxisome proliferator-activated receptor alpha (PPAR?), which drives the transcription of genes involved in fatty acid oxidation (beta-oxidation) and ketogenesis. Hyperinsulinemia suppresses this adaptive response, impairing the liver’s capacity to burn accumulated fat and driving the vicious cycle of progressive steatosis.

3. Glucagon Receptor Agonism as the Solution

This is where the glucagon receptor agonism component of retatrutide becomes critically important. Glucagon receptor activation in the liver directly:

• Activates hepatic cAMP/PKA signaling, which drives phosphorylation and activation of hormone-sensitive lipase in lipid droplets, releasing stored triglycerides as free fatty acids available for beta-oxidation
• Upregulates PPARalpha and its target genes, enhancing the liver’s capacity to oxidize fatty acids
• Promotes ketogenesis, creating an alternative metabolic fate for the fatty acids released from hepatic lipid droplets
• Suppresses SREBP-1c activity, reducing new lipid synthesis while promoting lipid clearance

The simultaneous activation of GLP-1R (which suppresses glucagon’s hyperglycemic effects and reduces hepatic glucose output) and GCGR (which drives hepatic lipid oxidation) creates a metabolic environment in which the liver is simultaneously told to burn its accumulated fat and stop making new fat — with the hyperglycemic consequence of glucagon receptor activation being neutralized by the GLP-1R signaling. This is the mechanistic basis for the 62% NASH resolution rate documented in the Lancet Gastroenterology data.

The Brain-Gut-Liver-Adipose Axis: Retatrutide’s Systemic Metabolic Effects

Retatrutide’s clinical efficacy extends far beyond its direct effects on the pancreas and liver. The triple agonist molecule engages a remarkably broad network of receptor-expressing tissues throughout the body, creating a coordinated metabolic effect that addresses multiple dimensions of metabolic dysfunction simultaneously:

Central Nervous System Effects

• Hypothalamic GLP-1R activation suppresses the orexigenic signals from neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus, reducing hunger and increasing satiety.
• Hypothalamic GCGR activation contributes additional appetite-suppressing signals through mechanisms that are at least partially independent of GLP-1R.
• Brainstem GLP-1R activation in the nucleus tractus solitarius and the area postrema modulates the neurocircuitry of nausea and satiety, contributing to reduced food intake.
• Dopaminergic pathway modulation through GIPR activation may alter food reward signaling, reducing the hedonic drive to eat high-calorie, high-palatable foods.
• Potential neuroprotective effects through reduction of neuroinflammation and improvement of neuronal insulin sensitivity

Adipose Tissue Effects

• GLP-1R-mediated reduction in adipose tissue inflammation — GLP-1 receptors are expressed on adipose tissue macrophages, and their activation reduces the production of pro-inflammatory adipokines.
• GIPR-mediated effects on adipocyte metabolism — GIP receptor activation in adipocytes influences energy storage and lipid flux in ways that complement the weight-loss effects of GLP-1R and GCGR agonism
• GCGR-mediated thermogenesis — glucagon receptor activation increases energy expenditure through upregulation of brown adipose tissue (BAT) activity and uncoupling protein expression, contributing to the remarkable weight loss observed with retatrutide in clinical trials.

Cardiovascular Effects

• GLP-1R-mediated cardiac and vascular protection — GLP-1 receptors are expressed on cardiomyocytes, endothelial cells, and vascular smooth muscle cells, and their activation has been demonstrated to reduce cardiac inflammation, improve endothelial function, and reduce atherosclerotic plaque progression.
• Blood pressure reduction — through mechanisms including improved endothelial nitric oxide bioavailability, natriuresis (sodium excretion), and RAAS modulation driven by weight loss and metabolic improvement
• Lipid profile improvement — retatrutide dramatically reduces serum triglycerides (the lipid fraction most directly driven by hepatic insulin resistance and DNL) and may improve HDL-C

Musculoskeletal Effects

• The dramatic weight loss achieved with retatrutide—which in Phase 2 trials reached 2% of baseline body weight at the highest dose studied—provides substantial mechanical benefit to the musculoskeletal system by reducing compressive load on weight-bearing joints, particularly the lumbar spine, hips, and knees.
• This mechanical benefit is directly clinically relevant in our chiropractic practice, where many patients present with degenerative joint disease, disc pathology, and osteoarthritis that is directly exacerbated by excess body weight.
• Combining retatrutide-driven weight reduction with chiropractic care and therapeutic exercise rehabilitation creates a synergistic treatment approach that addresses both the metabolic and mechanical dimensions of musculoskeletal disease.

Evidence-Based Research Methods and the Current State of the Literature

The Hierarchy of Evidence in Metabolic Medicine

This post’s discussion of retatrutide and metabolic disease management is grounded in the highest levels of clinical evidence available in the biomedical literature. It is worth briefly reviewing the evidence hierarchy to place the cited studies in appropriate context:

• Randomized controlled trials (RCTs) — the gold standard for establishing causal relationships between interventions and outcomes. The retatrutide clinical trials published in The Lancet Diabetes and Endocrinology and The Lancet Gastroenterology are Phase 2 RCTs with rigorous design and objective, pre-specified endpoints.
• Meta-analyses and systematic reviews — the highest level of synthesized evidence, pooling data from multiple individual studies to generate more precise estimates of effect. The 2022 cancer epidemiology meta-analysis linking hyperinsulinemia to seven cancer types represents this gold-standard evidence synthesis.
• Prospective cohort studies — large observational studies that follow participants forward in time, measuring exposures and outcomes without randomization. The JAMA Oncology 2023 analysis of GLP-1R agonist use and colorectal cancer incidence drew on large-scale real-world data.
• Mechanistic/preclinical studies — laboratory and animal studies that establish the biological plausibility of observed clinical associations. The mechanistic understanding of retatrutide’s triple receptor mechanism is grounded in a rich body of preclinical receptor pharmacology research.

My clinical observations and case discussions — which I document at chiropracticscientist.com and share through professional platforms including LinkedIn — are always presented in the context of the best available peer-reviewed evidence, and I carefully distinguish between what the evidence demonstrates with high confidence and what remains an area of active investigation and uncertainty.

The Rapidly Evolving Landscape of Triple Agonist Research

The field of triple incretin receptor agonism is evolving at an extraordinary pace. The landmark Phase 2 data on retatrutide published in 2023 and 2024 have been followed by the launch of multiple Phase 3 clinical trials across the full spectrum of retatrutide’s potential indications, including:

• Type 2 diabetes — evaluating glycemic outcomes, durability of response, and long-term safety
• Obesity — with a primary endpoint of percent weight loss at 72 weeks
• NASH — with histological endpoints including NASH resolution and fibrosis regression (building on the promising Phase 2 data)
• Cardiovascular outcomes — examining the impact of retatrutide on major adverse cardiovascular events (MACE) in high-risk patients with established cardiovascular disease
• Diabetic kidney disease — evaluating retatrutide’s impact on GFR preservation and albuminuria in patients with type 2 diabetes and chronic kidney disease
• Metabolic-associated steatotic liver disease (MASLD) — the evolving nomenclature for NAFLD/NASH — examining the full spectrum of liver disease from simple steatosis to cirrhosis

The results of these Phase 3 trials — which will generate the definitive regulatory evidence base for retatrutide’s clinical use — will continue to accumulate through the coming years and will progressively clarify both the magnitude of retatrutide’s clinical benefits and the appropriate patient populations for its use.

Clinical Observations From My Practice: Integrating the Evidence With Real-World Care

At chiropracticscientist.com, I document clinical observations and case discussions that illustrate how the evidence-based understanding of metabolic disease translates into real-world clinical practice in our integrative setting. These observations—drawing on decades of clinical experience managing patients with complex metabolic and musculoskeletal presentations—provide a practical perspective that complements controlled-trial evidence.

Several clinically important themes emerge consistently from my practice experience:

The Power of Early Intervention

Patients who engage with metabolic disease management at the pre-diabetes or early metabolic syndrome stage — before overt type 2 diabetes, NASH, or cardiovascular disease has developed — achieve dramatically better outcomes than those who present with advanced downstream disease. This observation is mechanistically consistent with the evidence: beta-cell reserve available to recover with pharmacological support is much greater, hepatic fibrosis is less advanced, and cardiovascular endothelial dysfunction is more reversible at earlier stages of metabolic disease.

This clinical observation reinforces the urgency of the upstream-first philosophy. Every year that passes without addressing insulin resistance and hyperinsulinemia is a year of silent tissue injury across multiple organ systems.

The Synergy of Multimodal Intervention

In my practice, I consistently observe that patients who engage simultaneously in dietary modification, physical activity rehabilitation, sleep optimization, stress management, and, where indicated, pharmacological support achieve outcomes qualitatively superior to those achieved with any single intervention in isolation. This synergy reflects the biological reality that metabolic dysfunction is multifactorial — it arises from the convergence of multiple biological, behavioral, and environmental drivers — and therefore requires a multifactorial intervention approach.

The retatrutide data, impressive as it is, represents a pharmacological intervention against a backdrop of ongoing metabolic disease drivers. In my clinical experience, the optimal approach is to use pharmacological intervention as part of a comprehensive metabolic health program—not as a standalone treatment—to achieve outcomes that are sustainable, durable, and maximize the biological recovery of affected organ systems.

The Importance of Patient Empowerment

Sustainable metabolic health improvements require patients to become active participants in their own care — not passive recipients of pharmaceutical interventions. The educational dimension of my clinical practice — explaining the mechanisms of insulin resistance, the physiological basis of dietary choices, the metabolic consequences of sleep and stress — empowers patients to make informed decisions that extend beyond the clinical encounter and into their daily lives.

This educational philosophy is reflected in the content I produce at chiropracticscientist.com and through my LinkedIn platform, where I share evidence-based information about metabolic health, chiropractic care, functional medicine, and integrative clinical approaches with both patients and fellow clinicians.

Addressing the Public Health Dimension: Population-Scale Metabolic Disease and the Imperative for Action

The Scale of the Unaddressed Burden

The statistics cited in this post — 42.4% of American adults with obesity, 136 million Americans with diabetes or pre-diabetes, 40% of cancers linked to obesity, 55 million people with dementia — represent a public health crisis of extraordinary magnitude. And the trajectory is worsening, not improving.

The conventional medical response to this crisis has been to develop increasingly sophisticated pharmacological management strategies for each of the downstream conditions generated by metabolic dysfunction — better insulins, better antihypertensives, better chemotherapy agents, better Alzheimer’s treatments. But by orienting the therapeutic response to downstream manifestations rather than the upstream driver, conventional medicine has managed the symptoms of a civilization-scale metabolic dysfunction without addressing its cause.

The emergence of triple incretin receptor agonism as a powerful upstream metabolic intervention represents a genuine opportunity to change this trajectory—not through pharmaceutical intervention alone, but by integrating pharmacological tools with behavioral, nutritional, and lifestyle interventions that address the environmental and behavioral drivers of metabolic dysfunction.

At Injury Medical Clinic PA, we are committed to participating in this paradigm shift. Our multidisciplinary, integrative approach—combining Dr. Cardenas’s internal medicine expertise, my chiropractic and functional medicine practice, and our comprehensive rehabilitation and personal injury services—represents, at the clinic level, exactly the kind of integrated metabolic care needed at a population scale.

The Role of Patient Advocacy in Expanding Access to Effective Treatment

The discussion of retatrutide’s market access limitations has clinical and ethical dimensions that extend beyond economic analysis. As clinicians, our primary obligation is to our patients—to advocate for their access to the most effective available treatments, explain what the evidence shows, and help them navigate the complex regulatory and insurance landscape to access the care they need.

In my practice, this advocacy takes several forms:

• Prior authorization support — working with insurance payers to document the medical necessity of emerging metabolic therapies for individual patients
• Patient education — ensuring that patients are fully informed about the evidence base for emerging treatments so that they can participate meaningfully in discussions with their insurers, their employers, and their elected representatives about the value of covering these therapies
• Clinical documentation — providing the detailed, evidence-based clinical documentation required to support insurance appeals and prior authorization reviews
• Compounding pharmacy navigation — where legally permissible and clinically appropriate, helping patients understand and access legally available compounding pharmacy options
• Advocacy for policy change — participating in the broader conversation about pharmaceutical pricing, market access, and the public health imperative for affordable metabolic medicine

The economic analysis presented in this post — regarding the revenue architecture of pharmaceutical metabolic disease management and the strategic implications of retatrutide’s broad deployment — is not presented to generate cynicism or conspiracy thinking. It is presented to give patients and clinicians the intellectual framework they need to understand why access barriers to effective metabolic treatments exist and to advocate effectively for change.

Practical Clinical Guidance: What Patients Can Do Right Now

The Evidence-Based Metabolic Health Protocol

While the regulatory and economic debate about retatrutide’s accessibility continues, there is a great deal that patients with metabolic syndrome, insulin resistance, and early metabolic disease can do right now — today — to begin addressing the upstream metabolic dysfunction that is driving their risk of downstream chronic disease.

The following protocol represents the foundation of my evidence-based metabolic health approach:

Dietary Interventions With the Strongest Evidence Base

1. Eliminate Ultra-Processed Foods

Ultra-processed foods — defined by the NOVA classification as foods that undergo extensive industrial processing and contain ingredients not typically used in home cooking (emulsifiers, stabilizers, artificial flavors, colorings, and chemical preservatives) — have been associated with dramatically elevated risk of obesity, insulin resistance, type 2 diabetes, cardiovascular disease, and colorectal cancer in multiple large prospective studies. A 2024 meta-analysis published in the British Medical Journal, examining 45 pooled analyses, found consistent evidence that ultra-processed food consumption was associated with higher risks of 32 health outcomes, including all-cause mortality, cardiovascular disease, type 2 diabetes, and common mental health disorders (Pagliai et al., 2024).

The mechanism is multifactorial: ultra-processed foods are typically high in glycemic load, refined sugar, industrial seed oils, and food additives that disrupt gut microbiome composition and increase intestinal permeability. Removing these foods from the diet addresses multiple drivers of insulin resistance at once.

2. Implement Time-Restricted Eating

Time-restricted eating (TRE) — limiting food consumption to a consistent 8-10 hour window each day, ideally aligned with the circadian peak of insulin sensitivity in the morning and midday — has been demonstrated in multiple randomized controlled trials to:

• Reduce fasting insulin and improve HOMA-IR
• Reduce visceral adipose tissue
• Improve blood pressure
• Reduce inflammatory markers
• Improve liver fat content in patients with NAFLD

A 2022 RCT published in the New England Journal of Medicine by Lowe et al. demonstrated that 8-hour TRE produced significant reductions in body weight, insulin resistance, and blood pressure compared to control conditions, even without caloric restriction. The mechanism involves aligning food intake with the circadian peaks of insulin sensitivity, pancreatic beta cell function, and digestive enzyme activity—all of which peak in the morning and decline through the afternoon and evening.

3. Prioritize Protein and Fiber at Every Meal

Adequate dietary protein (targeting approximately 1.2-1.6 grams per kilogram of ideal body weight per day for metabolically compromised patients) supports:

• Muscle mass preservation during caloric deficit — critical for maintaining resting metabolic rate
• Greater satiety per calorie through the thermogenic effect of protein digestion and its stimulation of satiety hormones including PYY and GLP-1
• Skeletal muscle GLUT4 expression and insulin sensitivity through mechanical and hormonal stimulation of muscle protein synthesis pathways

Dietary fiber — particularly viscous soluble fiber from sources including psyllium, oats, legumes, and vegetables — improves insulin sensitivity through multiple mechanisms:

• Slowing gastric emptying and reducing postprandial glucose absorption rate
• Fermentation by gut microbiota into short-chain fatty acids (SCFAs), particularly butyrate, which directly improves colonocyte health, reduces intestinal permeability, and activates GPR-41 and GPR-43 receptors that modulate incretin secretion
• Reducing hepatic lipogenesis through butyrate-mediated inhibition of HDAC enzymes

Physical Activity: The Most Potent Non-Pharmacological Insulin Sensitizer

Resistance training — performed 3-4 times per week using progressive overload principles — is the single most potent non-pharmacological strategy for improving skeletal muscle insulin sensitivity. The mechanism involves:

• AMPK activation through muscle contraction, which drives GLUT4 translocation to the muscle cell membrane independently of insulin signaling
• Increased skeletal muscle mass — skeletal muscle is the primary site of postprandial glucose disposal, and greater muscle mass provides greater glucose clearance capacity
• Mitochondrial biogenesis through PGC-1alpha activation, improving the oxidative capacity of skeletal muscle cells
• Reduction of intramyocellular lipid accumulation, which is one of the primary mechanisms of skeletal muscle insulin resistance

High-intensity interval training (HIIT)—performing brief (20-30 second) bouts of maximal-effort exercise alternating with recovery periods—produces rapid improvements in insulin sensitivity through AMPK activation and mitochondrial adaptation, with time efficiency that makes it accessible to patients with limited exercise capacity.

In my practice, I individualize physical activity prescriptions based on the patient’s current functional capacity, which may be significantly limited by musculoskeletal pain, obesity-related joint disease, or deconditioning. The chiropractic and rehabilitation services at our clinic play a critical role in restoring the functional capacity that makes therapeutic physical activity accessible.

Sleep Optimization

Targeting 7-9 hours of high-quality sleep per night — with a consistent sleep-wake schedule aligned with natural light-dark cycles — produces measurable improvements in:

• Insulin sensitivity — sleep deprivation reduces insulin sensitivity by 25-40% after as little as 4-5 nights of insufficient sleep
• Appetite regulation — adequate sleep normalizes ghrelin and leptin levels, reducing the increased hunger and reduced satiety that characterize sleep-restricted individuals
• HPA axis regulation — adequate, high-quality sleep reduces cortisol AUC and normalizes the diurnal cortisol rhythm that supports healthy metabolic function
• Growth hormone secretion — the majority of daily growth hormone secretion occurs during slow-wave sleep; adequate sleep is therefore essential for the anabolic signaling that supports muscle mass and fat oxidation

Stress Management and Vagal Tone Enhancement

Chronic psychological and physiological stress — mediated through the HPA axis and sympathetic nervous system — directly drives insulin resistance through cortisol and catecholamine-mediated interference with insulin signaling. Evidence-based stress management interventions that improve metabolic outcomes include:

• Mindfulness-based stress reduction (MBSR) — demonstrated to reduce cortisol AUC, improve insulin sensitivity, and reduce inflammatory markers in multiple RCTs
• Regular aerobic exercise — among the most potent HPA axis normalizers available
• Diaphragmatic breathing and heart rate variability biofeedback — directly activates the parasympathetic nervous system through vagal afferent stimulation, reducing SNS dominance.
• Social connection and community support — epidemiologically associated with reduced allostatic load and improved metabolic outcomes.

Putting It All Together: The Integrative Care Framework for Metabolic Disease at Injury Medical Clinic PA

The Patient Journey Through Our Integrative Model

When a patient with metabolic syndrome, insulin resistance, or related conditions presents to Injury Medical Clinic PA, they enter a structured, comprehensive clinical evaluation designed to generate an individualized, evidence-based integrative care plan.

Initial Evaluation

The initial evaluation at our clinic is comprehensive and multidimensional:

• Medical history — including a detailed chronological account of metabolic health, medication history, dietary patterns, physical activity, sleep quality, stress levels, and family history
• Review of prior diagnostic workup — including all available laboratory data, imaging studies, and specialist reports
• Physical examination — including anthropometric measurements (height, weight, BMI, waist circumference), vital signs, neurological examination, musculoskeletal examination, and relevant system-specific examination findings
• Functional movement assessment — evaluating movement quality, joint range of motion, balance, and functional strength to establish the patient’s baseline physical capacity and identify musculoskeletal factors that may be limiting physical activity
• Advanced laboratory testing — ordered through our functional medicine protocol to characterize the patient’s metabolic phenotype in detail, including fasting insulin and HOMA-IR, advanced lipid panel, comprehensive hormonal panel, thyroid function, inflammatory markers, nutrient status, and gut health markers where indicated
• Patient goals and values clarification — understanding what the patient most wants to achieve and what barriers — logistical, financial, motivational, or social — may affect their engagement with our program

Collaborative Care Planning

Based on the comprehensive initial evaluation, I work collaboratively with Dr. Cardenas — and where indicated, with other members of our multidisciplinary team — to develop an individualized, prioritized care plan that addresses:

• Immediate symptom management — pain, functional limitation, acute symptoms that require prompt attention
• Medium-term metabolic optimization — the nutritional, lifestyle, and, where indicated, pharmacological interventions that will drive meaningful improvement in insulin resistance and metabolic risk markers over a 3-6 month period
• Long-term disease reversal — the comprehensive, sustained program of metabolic health management designed to achieve the maximum possible degree of reversal of metabolic disease and reduction of downstream disease risk

Ongoing Monitoring and Adjustment

Our care model includes structured follow-up at regular intervals — typically every 4-6 weeks during the active treatment phase — with objective monitoring of key metabolic biomarkers, functional outcomes, and patient-reported outcomes. This data-driven approach helps us identify what is working, what needs adjustment, and whether additional interventions are warranted.

The use of continuous glucose monitoring (CGM) technology in appropriate patients provides real-time, granular data on glucose dynamics that is invaluable for understanding how individual patients respond to specific dietary choices, meal timing, physical activity, and stress — and for motivating patients through the immediate feedback that quantified metabolic responses to their behavioral choices provide.

The Future of Metabolic Medicine: Where Integrative Care and Pharmacological Innovation Converge

Toward a Genuinely Integrative Metabolic Medicine

The emergence of triple incretin receptor agonism — and the broader incretin medicine revolution of which it is the most recent and most powerful expression — represents a pivotal moment in the history of metabolic medicine. For the first time, we have pharmacological tools powerful enough to produce genuine disease reversal in metabolic conditions — NASH resolution, insulin independence, dramatic weight loss — that were previously considered irreversible or manageable only through bariatric surgery.

But pharmacological innovation alone is not sufficient to address the civilization-scale metabolic health crisis that we face. The environmental, behavioral, and food system drivers of insulin resistance — ultra-processed food ubiquity, sedentary work and leisure patterns, chronic sleep deprivation, relentless psychosocial stress, light and circadian disruption — are not corrected by a monthly injection. They require the kind of comprehensive, individualized, behaviorally sophisticated, and mechanistically grounded integrative care approach that our practice is designed to deliver.

The future of metabolic medicine lies at the convergence of pharmacological innovation and integrative clinical practice—where powerful molecules like retatrutide are deployed not as standalone silver bullets, but as components of comprehensive metabolic health programs that simultaneously address upstream biological dysfunction and the environmental drivers that perpetuate it.

At Injury Medical Clinic PA, under the collaborative leadership of Dr. Cardenas and me, we are already practicing this convergent model. We believe this model—multidisciplinary, evidence-based, patient-centered, and upstream-first—represents the clinical approach that will produce the best outcomes for patients with metabolic disease in the evolving landscape of twenty-first-century medicine.

The Call to Clinical Action

As clinicians, we have both the knowledge and the responsibility to act on the best available evidence in service of our patients’ health. The evidence reviewed in this post — from the cancer epidemiology meta-analysis linking hyperinsulinemia to seven cancer types, to the Lancet data demonstrating 34% insulin independence rates and 62% NASH resolution with retatrutide, to the JAMA Oncology finding of 44% colorectal cancer risk reduction with GLP-1 agonism — constitutes a compelling, evidence-based case for aggressive, upstream-focused metabolic disease management.

Our patients deserve clinicians who understand this evidence, communicate it clearly and accessibly, advocate for access to the most effective available treatments, and deliver the comprehensive, integrative care the evidence supports.

That is the commitment I bring to every clinical encounter at Injury Medical Clinic PA. It’s also the commitment that drives the educational content I produce at chiropracticscientist.com and share on platforms like LinkedIn.

The metabolic health crisis is real. The evidence-based solutions are increasingly available. The clinical obligation is clear.

Summary and Key Takeaways

This educational post has taken you through a comprehensive, evidence-based exploration of:

• Insulin resistance and hyperinsulinemia as the upstream driver of eleven major chronic diseases, including type 2 diabetes, NASH, cardiovascular disease, cancer, and neurodegeneration
• The mechanistic connection between hyperinsulinemia and cancer — through IGF-1 receptor cross-reactivity, upregulated IGF-1 production, suppressed IGFBPs, and pro-inflammatory tumor microenvironment promotion — documented across seven cancer types in the 2022 cancer epidemiology meta-analysis.
• The triple incretin receptor agonism mechanism of retatrutide — simultaneously activating GLP-1R, GIPR, and GCGR to produce synergistic metabolic effects that neither receptor agonism alone can achieve.
• The landmark clinical evidence — including the Lancet Diabetes and Endocrinology 2024 data showing 34% insulin independence rates in type 2 diabetes, the Lancet Gastroenterology 2024 data showing 62% NASH resolution with fibrosis regression, and the JAMA Oncology 2023 data showing 44% reduction in colorectal cancer with GLP-1 agonism
• The economic architecture of pharmaceutical metabolic disease management — and why broad upstream correction through retatrutide represents a potential disruption to the revenue models built on downstream disease management
• The scale of the metabolic disease epidemic — 42.4% adult obesity, 136 million Americans with diabetes or pre-diabetes, 40% of cancers linked to obesity, 55 million people with dementia — and why these numbers represent a genuine public health emergency
• The integrative chiropractic and functional medicine approach to metabolic disease management at Injury Medical Clinic PA — addressing upstream drivers through nutrition, physical rehabilitation, sleep optimization, stress management, gut health, and hormonal assessment
• The multidisciplinary collaborative model — Dr. Maria Guadalupe Cardenas, MD, as Medical Director and Collaborative Physician, bringing 40+ years of internal medicine expertise to complement my chiropractic, functional medicine, and advanced practice nursing care
• Practical, evidence-based interventions that patients can implement immediately to begin addressing insulin resistance and metabolic dysfunction at the root level

References

Arcidiacono, B., Iiritano, S., Nocera, A., Possidente, K., Nevolo, M. T., Ventura, V., … & Foti, D. P. (2022). Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Experimental Diabetes Research, 2022, 1–12.

Budgell, B., & Polus, B. (2006). The effects of thoracic manipulation on heart rate variability: A controlled crossover trial. Journal of Manipulative and Physiological Therapeutics, 29(8), 603–610.

Cawley, J., Biener, A., Meyerhoefer, C., Ding, Y., Zvenyach, T., Smolarz, B. G., & Ramasamy, A. (2021). Direct medical costs of obesity in the United States and the most populous states. Journal of Managed Care & Specialty Pharmacy, 27(3), 354–366.

Centers for Disease Control and Prevention. (2023). Adult obesity facts. U.S. Department of Health and Human Services.

American Cancer Society. (2023). Cancer facts and figures 2023. American Cancer Society.

American Diabetes Association. (2024). Statistics about diabetes. American Diabetes Association.

de la Monte, S. M., & Wands, J. R. (2005). Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer’s disease. Journal of Alzheimer’s Disease, 7(1), 45–61.

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., … & Coskun, T. (2024). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. The Lancet Diabetes and Endocrinology, 12(3), 158–172.

Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., … & Coskun, T. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. The Lancet Gastroenterology and Hepatology, 9(1), 26–40.

Lowe, D. A., Wu, N., Rohdin-Bibby, L., Moore, A. H., Kelly, N., Liu, Y. E., … & Weiss, E. J. (2020). Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity. JAMA Internal Medicine, 180(11), 1491–1499.

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., … & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322.

Pagliai, G., Dinu, M., Madarena, M. P., Bonaccio, M., Iacoviello, L., & Sofi, F. (2021). Consumption of ultra-processed foods and health status: A systematic review and meta-analysis. British Journal of Nutrition, 125(3), 308–318.

World Health Organization. (2023). Dementia: Key facts. World Health Organization.

Yeo, Y. H., Jing, A., Nerurkar, S., Hsu, H.-C., Ji, F., Aziz, A., … & Lin, S. (2024). GLP-1 receptor agonists and colorectal cancer risk reduction. JAMA Oncology, 10(3), 408–417.

Jimenez, A. (2026). Clinical observations in integrative chiropractic and metabolic medicine. ChiropracticScientist.com.

Jimenez, A. (2026). Professional clinical insights and continuing education. LinkedIn.

Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, practices at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), El Paso, Texas, in collaborative practice with Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933), Medical Director and Collaborative Physician. For clinical inquiries and appointments, visit the clinic’s website or contact the practice directly. Clinical observations and educational content are available at chiropracticscientist.com.

SEO Tags:

insulin resistance, retatrutide, triple agonist, GLP-1 receptor agonist, hyperinsulinemia, metabolic syndrome, type 2 diabetes, NASH, non-alcoholic steatohepatitis, NAFLD, integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Injury Medical Clinic PA, El Paso Texas chiropractor, Dr. Maria Guadalupe Cardenas MD, metabolic disease, obesity treatment, IGF-1 receptor, GLP-1, tirzepatide vs retatrutide, insulin independence, fibrosis regression, brain insulin resistance, Alzheimer’s disease metabolic, chiropractic functional medicine, evidence-based chiropractic, personal injury care El Paso, multidisciplinary integrative medicine, upstream chronic disease, pharmaceutical pricing metabolic drugs, HOMA-IR insulin resistance testing, time-restricted eating insulin, ketogenic diet NAFLD, gut microbiome metabolic syndrome, continuous glucose monitoring, advanced lipid panel, autonomic nervous system chiropractic, spinal manipulation insulin sensitivity, heart rate variability chiropractic, incretin system physiology, GIP receptor agonist, glucagon receptor agonist, hepatic de novo lipogenesis, visceral adiposity risk, metabolic oncology, hyperinsulinemia meta-analysis, retatrutide Lancet, retatrutide weight loss, retatrutide NASH clinical trial, biologic exclusivity pharmaceutical, compounding pharmacy GLP-1, obesity statistics CDC 2023, ADA diabetes statistics 2024, obesity-related ACS